We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Prognostic Test to Help Predict Prostate Cancer Metastasis

By LabMedica International staff writers
Posted on 26 Jan 2024
Print article
Image: Stromal cells may help predict prostate cancer metastasis (Photo courtesy of Weill Cornell)
Image: Stromal cells may help predict prostate cancer metastasis (Photo courtesy of Weill Cornell)

Stromal cells, non-cancerous cells present in all organs, play a key role in wound healing, blood vessel formation, and providing structural support to tissues. Recent research has shown that tumors often manipulate these stromal cells to create an environment conducive to their growth and survival. However, the exact functions of stromal cells in various cancers are just beginning to be understood. Now, a new study has revealed that these stromal cells, which are found in and around prostate tumors, could be instrumental in determining the likelihood of these tumors spreading. These findings also suggest that stromal cells might be viable targets in developing treatments for prostate cancer.

At Weill Cornell Medicine (New York, NY, USA), researchers conducted a detailed analysis of stromal cells in prostate cancer. This study, which is the most comprehensive of its kind, used mouse models representing different stages of prostate tumor progression and samples from human prostate tumors. Employing single-cell RNA sequencing combined with AI-driven analysis, the team identified eight distinct subpopulations of tumor-associated stromal cells in both mouse and human tumors. These subpopulations were characterized by unique gene activity patterns influenced by the presence of a tumor, its acquisition of cancer-driving mutations, and its progression to metastasis.

The study revealed a significant finding: stromal cells around prostate tumors often create a molecular environment resembling that of bone. This environment seemingly prepares tumor cells for bone metastasis, a common progression in prostate cancer. The researchers identified various signaling proteins and networks that become aberrantly active or inactive during these transitions. These signaling dynamics between tumor cells, stromal cells, and immune cells may present new avenues for prostate cancer treatment aimed at preventing metastasis. Beyond identifying potential therapeutic targets, the research team is looking to use their findings to develop prognostic tests based on tumor-associated stromal cells. These tests could predict the aggressiveness of prostate tumors, thereby assisting physicians in making more informed treatment decisions.

“These results illuminate the substantial impact of stromal cells on prostate cancer progression, and point to the possibility of new prognostic and therapeutic strategies,” said study senior author Dr. Massimo Loda. “One could even imagine using such a test on biopsy samples where no tumor tissue is found. If signs in the stromal cells point to the likely existence of a tumor, maybe an aggressive one, then perhaps you should biopsy again.”

Related Links:
Weill Cornell Medicine

New
Platinum Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Rickettsia Conorii Assay
RICKETTSIA CONORII ELISA

Print article
77 ELEKTRONIKA

Channels

Clinical Chemistry

view channel
Image: PhD student and first author Tarek Eissa has analyzed thousands of molecular fingerprints (Photo courtesy of Thorsten Naeser / MPQ / Attoworld)

Screening Tool Detects Multiple Health Conditions from Single Blood Drop

Infrared spectroscopy, a method using infrared light to study the molecular composition of substances, has been a foundational tool in chemistry for decades, functioning similarly to a molecular fingerprinting... Read more

Hematology

view channel
Image: The Truvian diagnostic platform combines clinical chemistry, immunoassay and hematology testing in a single run (Photo courtesy of Truvian Health)

Automated Benchtop System to Bring Blood Testing To Anyone, Anywhere

Almost all medical decisions are dependent upon laboratory test results, which are essential for disease prevention and the management of chronic illnesses. However, routine blood testing remains limited worldwide.... Read more

Immunology

view channel
Image: The blood test measures lymphocytes  to guide the use of multiple myeloma immunotherapy (Photo courtesy of 123RF)

Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy

Multiple myeloma, a type of blood cancer originating from plasma cells in the bone marrow, sees almost all patients experiencing a relapse at some stage. This means that the cancer returns even after initially... Read more

Microbiology

view channel
Image: Ultra-Rapid Antimicrobial Susceptibility Testing (uRAST) revolutionizing traditional antibiotic susceptibility testing (Photo courtesy of Seoul National University)

Ultra-Rapid Culture-Free Sepsis Test Reduces Testing Time from Days to Hours

Sepsis, a critical emergency condition, results from an overactive inflammatory response to pathogens like bacteria or fungi in the blood, leading to organ damage and the possibility of sudden death.... Read more

Pathology

view channel
Image: The AI model can distinguish different stages of DCIS from inexpensive and readily available breast tissue images (Photo courtesy of David A. Litman/Shutterstock)

AI Model Identifies Breast Tumor Stages Likely To Progress to Invasive Cancer

Ductal carcinoma in situ (DCIS) is a non-invasive type of tumor that can sometimes progress to a more lethal form of breast cancer and represents about 25% of all breast cancer cases. Between 30% and 50%... Read more

Industry

view channel
Image: Beckman Coulter will utilize the ALZpath pTau217 antibody to detect key biomarker for Alzheimer\'s disease on its DxI 9000 immunoassay analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter Licenses Alzpath's Proprietary P-tau 217 Antibody to Develop Alzheimer's Blood Test

Cognitive assessments have traditionally been the primary method for diagnosing Alzheimer’s disease, but this approach has its limitations as symptoms become apparent only after significant brain changes... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.